| | |
Total patients
|
CCRT
|
CCRT followed by adjuvant chemotherapy
|
P
+ value
|
|---|
|
Case
| |
120
|
30
|
90
| |
|
Median age, years (range)
|
62.4 (24.2~87.0)
|
63.4 (24.2~74.4)
|
62.1 (38.8~87.0)
|
0.87
|
|
Men (%)
| |
89 (74.2)
|
20 (66.7)
|
69 (76.7)
|
0.25
|
|
Performance
|
ECOG 0-1
|
111 (92.5)
|
28 (93.3)
|
83 (92.2)
|
0.73
|
| |
ECOG 2
|
9 (7.5)
|
2 (6.7)
|
7 (7.8)
| |
|
T stage (%)
|
T1
|
20 (16.7)
|
4 (13.3)
|
16 (17.8)
|
0.53
|
| |
T2
|
33 (27.5)
|
6 (20.0)
|
27 (30.0)
| |
| |
T3
|
51 (42.5)
|
16 (53.3)
|
35 (38.9)
| |
| |
T4
|
16 (13.3)
|
4 (13.3)
|
12 (13.3)
| |
|
N stage (%)
|
N0
|
77 (64.2)
|
18 (60.0)
|
59 (65.6)
|
0.58
|
| |
N1
|
43 (35.8)
|
12 (40.0)
|
31 (34.4)
| |
|
Stage (%)
|
IA
|
13 (10.8)
|
2 (6.7)
|
11 (12.2)
|
0.73
|
| |
IB
|
27 (22.5)
|
5 (16.7)
|
22 (24.4)
| |
| |
IIA
|
29 (24.2)
|
9 (30.0)
|
20 (22.2)
| |
| |
IIB
|
35 (29.2)
|
10 (33.3)
|
25 (27.8)
| |
| |
III
|
16 (13.3)
|
4 (13.3)
|
12 (13.3)
| |
|
RM status (%)
|
Negative
|
79 (65.8)
|
19 (63.3)
|
60 (66.7)
|
0.74
|
| |
Positive
|
41 (34.2)
|
11 (36.7)
|
30 (33.3)
| |
|
CA 19-9 (%)
|
≤ 60 U/ml
|
57 (47.5)
|
17 (56.7)
|
40 (44.4)
|
0.27
|
| |
> 60
|
62 (51.7)
|
13 (43.3)
|
49 (54.4)
| |
|
Tumor location (%)
|
Proximal
|
59 (49.2)
|
13 (43.3)
|
46 (51.1)
|
0.52
|
| |
Distal
|
55 (45.8)
|
15 (50.0)
|
40 (44.4)
| |
|
Histologic grade (%)
|
WD/MD
|
107 (89.2)
|
29 (96.7)
|
78 (86.7)
|
0.29
|
| |
PD
|
11 (9.2)
|
1 (3.3)
|
10 (11.1)
| |
|
Recurrence (%)
|
Local
|
22 (32.4)
|
5 (26.3)
|
17 (34.7)
|
0.51
|
| |
Systemic
|
46 (67.6)
|
14 (73.7)
|
32 (65.3)
| |
-
+Statistical value between CCRT and CCRT followed by adjuvant chemotherapy
- ECOG, Eastern Cooperative Oncology Group; RM, resection margin; WD, well differentiated; MD, moderate differentiated; PD, poor differentiated; CCRT, concurrent chemoradiation therapy.
